Clinical Trial Update: An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia [Phase 2]

View source ↗

Summary

An extension study of IMR-687 in adults with sickle cell anemia (Phase 2) is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• IMR-687

Snippet

Sponsor: Imara, Inc. | Conditions: Sickle Cell Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING